Warfarin is contraindicated during pregnancy, particularly during organogenesis (weeks 6-12). The risk of fetal bleeding remains throughout pregnancy due to the immature fetal liver. 2 Warfarin is not normally prescribed at any stage during pregnancy in Australia.
fibrillation in association with risk factors, particularly previous thromboembolism (transient ischaemic attack or ischaemic stroke), diabetes and hypertension. Warfarin is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors.
One of the most frequent indications for anticoagulation is reducing the risk of stroke associated with non-rheumatic atrial fibrillation, particularly in the elderly. The prevalence of atrial fibrillation approximately doubles with each advancing decade of age. Non-rheumatic atrial fibrillation is found in approximately 15% of all stroke patients. 3, 4 The average stroke rate among patients with atrial fibrillation is 5% per annum. With the ageing population stroke prevention in atrial fibrillation will continue to be a significant management issue.
Contraindications to warfarin therapy
Contraindications to warfarin are any localised or general physical condition or personal circumstance in which the hazard of haemorrhage might be greater than the potential clinical benefit of anticoagulation. These include:
■ haemorrhagic tendencies and blood dyscrasias ■ recent or contemplated surgery of the central nervous system or the eye ■ traumatic surgery resulting in large open surfaces.
Warfarin is contraindicated if the patient is unwilling or unable to comply with monitoring due to cognitive impairment, alcoholism, psychosis or problems with accessing services.
In the major interventional trials studying the efficacy of warfarin for stroke reduction in atrial fibrillation, patients considered at excessive risk of bleeding were excluded (Table 1) . These exclusion criteria resulted in the recruitment of a fit group with only a very small sub-group of very elderly people, so there are inherent problems in extrapolating the study results into everyday practice.
Introduction
Anticoagulation with warfarin significantly reduces the morbidity and mortality related to arterial and venous thromboembolism. For many patients the benefit is clear and the risk of harm is acceptable, so anticoagulation is indicated. Harm:benefit analysis in prescribing warfarin ( Fig. 1) The risk of major bleeding in the atrial fibrillation intervention trials was 1-4% per year, with an intracranial bleeding rate of 0.2-0.5% per year. The fatality rate mirrored the intracranial bleeding rate. 5 In observational studies of ambulatory patients the risk of major bleeding is 4-9% per annum. 6, 7 Major determinants of warfarin-induced bleeding include the intensity of anticoagulation, patient characteristics, the concomitant use of drugs that interfere with haemostasis, and the length of therapy. 5 Before prescribing warfarin the risk of bleeding should be evaluated and discussed with each patient. 8
Intensity of anticoagulation and duration of therapy
The risk of bleeding increases dramatically when the International Normalised Ratio (INR) exceeds 4.0. 9,10 An INR greater than 4.0 is probably the most important risk factor for intracranial haemorrhage, independent of the indication for warfarin. 5 The risk of major bleeding is greatest in the first month of therapy (3%) and decreases with time to 0.8% per month for the remainder of the first year and to 0.3% per month thereafter. 7
Patient characteristics Age
Atrial fibrillation is an increasingly important cause of stroke as patients get older. In the Framingham study the incidence of stroke due to atrial fibrillation increased from 1.5% for those aged 50-59 years to 23.5% for those aged 80-89 years. 11 The prevalence of atrial fibrillation in those over 80 years old reaches approximately 10%. 12 The results of studies conflict on whether age is an independent risk factor for bleeding. Advanced age is not itself a contraindication to warfarin. Studies in atrial fibrillation support the ongoing benefit of anticoagulation with increasing age.
Warfarin therapy reduces the risk of ischaemic stroke in patients with non-rheumatic atrial fibrillation from 7.4% to 2.3% per year. 13 Age is, however, a risk factor for more unstable prothrombin time results. For every 10-year increase in age there is a 15%
increase in the risk of anticoagulation having to be suspended because of a raised INR. 14 
Comorbidities and medication
Conditions associated with an increased risk of bleeding during warfarin therapy include treated hypertension, cerebrovascular disease, serious heart disease, renal insufficiency and malignancy. 5 Over time a person's comorbidities and medications accumulate. These increase the potential for interactions with warfarin.
The INR becomes unstable with the introduction, change in dose or suspension of many common drugs such as antibiotics.
Warfarin and aspirin combinations are associated with a high frequency of bleeding, even when combined with 'low intensity' warfarin therapy. 5 Some herbal preparations and large quantities of vitamin K-rich foods can also interfere with warfarin. 15 
Table 1
Exclusion criteria used in the major intervention trials of anticoagulation for patients with atrial fibrillation 13, 19 Bleeding disorder or abnormal coagulation at baseline A decision analysis model of the risks of central nervous system bleeding found that the propensity to fall is not a contraindication to the use of antithrombotic drugs (especially warfarin) in the elderly person with atrial fibrillation. 16 However, approximately 1 in 10 falls causes major injury, including fractures, and people who fall are much more likely to suffer other serious morbidity. There is insufficient evidence to know whether those who fracture a bone while on warfarin suffer greater morbidity and mortality.
There are factors that contribute to the risk of falls that may also have an impact on the ability to adhere to warfarin therapy and monitoring. These include cognitive and sensory impairment as well as poor mobility due to gait, balance and foot problems.
Often the general practitioner will be aware of other problems in addition to falls that preclude the safe and reliable use of anticoagulation.
Change in patient status
Each new diagnosis, treatment or major change in the 
Gastrointestinal bleeding
A similar analytical model has also been used to balance the risk of stroke and gastrointestinal bleeding in older patients with atrial fibrillation. 17 
Aspirin
When warfarin is contraindicated in patients with atrial fibrillation, aspirin should be given as it confers a 42% risk reduction compared to placebo. 13 This is inferior to warfarin and still increases the risk of bleeding (major bleeding rate of 1.4%
per year 13 ).
Reduced intensity regimens
Moderately sub-therapeutic levels of anticoagulation (INR Previous studies of fixed low doses of warfarin showed low rates of major bleeding. 5 A more recent study of long-term, low intensity treatment with warfarin (INR target 1.5-2.0) for the prevention of recurrent thromboembolism also found low rates of major haemorrhage 6 , while other research reported no difference in bleeding risk. 20 Another study has found that reduced intensity regimens result in more frequent strokes, that are more severe and lead to greater mortality, than regimens which aim for an INR greater than 2.0. This study found the stroke rate was no better than with aspirin and the bleeding complications were greater. 21 These findings suggest that the target INR should be at least 2.0.
Low molecular weight heparin
An alternative to warfarin is the extended use of low molecular 
Discontinuation of warfarin
Warfarin therapy should be discontinued when the risk of bleeding outweighs the potential benefit. Any decision to discontinue warfarin should only be made after discussion with the patient or carer. Once the decision is made the relevant clinical carers should be informed, and the reasoning and the harm:benefit analysis should be clearly identified and documented. This decision should be subsequently reviewed if clinical or social circumstances alter.
Future directions
New oral anticoagulants, particularly the oral direct thrombin inhibitors, appear promising. They are currently being evaluated for a variety of thrombotic disorders including atrial fibrillation.
Note
Two case studies accompany the electronic version of this article on the Australian Prescriber web site www.australianprescriber.com
